Chimeric antigen receptor (CAR) T-cell therapy has been a game changer in the treatment of B-cell malignancies, although their manufacturing process is complex and needs lymphodepletion, thus limiting their use. Researchers from Capstan Therapeutics Inc. have recently published data regarding an in vivo engineering approach to generate CAR T cells using targeted lipid nanoparticles (LNPs) for mRNA delivery to specific T-cell populations for the treatment of cancer and B-cell-mediated autoimmune diseases.
Researchers from Purdue University and the U.S. Centers for Disease Control and Prevention have recently developed a novel influenza vaccine candidate that uses a bovine adenoviral (BAd) vector to deliver nucleoprotein (NP) antigens from both influenza A and B viruses, along with an autophagy-inducing peptide (C5) to enhance cellular immune responses, particularly T-cell responses.
Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos. These studies aim to address the shortage of immunocompatible organ donors while shedding light on some of the most fundamental questions in developmental biology.
Systemic sclerosis (SSc) is a particularly severe form of fibrotic disease that affects multiple organs. SSc is the most deadly autoimmune rheumatic disease.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and damage of the joints. PET/CT imaging is a useful tool for early disease assessment and monitoring treatment efficacy.
Researchers from Lifordi Immunotherapeutics Inc. have developed a novel antibody-drug conjugate (ADC) called LFD-200 that aims to selectively deliver a potent glucocorticoid (GC) payload directly to immune cells. This strategy may potentially offer a new way to treat autoimmune and inflammatory conditions while minimizing systemic toxicity.
Dana-Farber Cancer Institute Inc. has synthesized tyrosine-protein phosphatase non-receptor type 6 (PTPN6; PTP-1C; SH-PTP1) activators reported to be useful for the treatment of autoimmune disease and cancer.
Systemic lupus erythematosus is a chronic autoimmune disease in which immune cells invade various organs and unleash harmful inflammatory responses. Estrogen may contribute to the condition, which would explain why it affects women over men in a 9:1 ratio.
CSPC Pharmaceutical Group Ltd. has entered into a strategic research collaboration agreement with Astrazeneca plc for the discovery and development of novel oral small-molecule candidates utilizing the group’s AI-driven, dual-engine efficient drug discovery platform.
Therapies involving B-cell depletion targeting CD19 or BCMA have shown efficacy in the treatment of B-cell malignancies. Recently, this approach has shown efficacy in the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis, by repopulation and resetting of B cells and immunoglobulins.
RSS
